HROW · Harrow, Inc.
Market Cap
$1.39B
Shares
37.49M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$272.3M
+36.4%
FY2025
Net Income
-$5.14M
+70.6%
FY2025
Gross Margin
75.05%
-0.3pp
FY2025
Operating Margin
11.21%
+6.8pp
FY2025
Diluted EPS
-$0.14
+71.4%
FY2025
Operating Cash Flow
$43.86M
+297.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 | FY2002 | FY2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $275.59M | $272.3M | $199.61M | $130.19M | $88.6M | $72.48M | $48.87M | $51.17M | $41.37M | $26.77M | $19.94M | $9.72M | $1.66M | $10K | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | -$5.44M | -$2.24M | -$2.5M | -$2.73M | -$3.03M | -$2.77M | -$1.11M | $29K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $73.64M | $67.93M | $49.25M | $39.64M | $25.38M | $18.21M | $14.46M | $16.75M | $16.52M | $13.51M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $201.96M | $204.37M | $150.37M | $90.55M | $63.21M | $54.26M | $34.41M | $34.42M | $24.85M | $13.27M | $10.11M | $4.51M | $567K | $10K | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | 75.05% | 75.33% | 69.55% | 71.35% | 74.87% | 70.41% | 67.26% | 60.07% | 49.56% | 50.7% | 46.42% | 34.16% | 100% | — | — | — | — | — | — | — | — | — | — | — | — | |
| $29.01M | $20.94M | $12.23M | $6.65M | $3.05M | $11.08M | $2.41M | $2.08M | $825K | $413K | $739K | $332K | $237K | $1.62M | $1.3M | $111.55K | $194.59K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $7.06M | $7.38M | $6.5M | $2.39M | $85.89K | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $17.96M | $17.57M | $12.5M | $8.09M | $5.99M | — | — | — | — | — | — | — | — | — | — | — | — | |
| $175.69M | $152.91M | $129.06M | $83.09M | $58.24M | $41.32M | $31.25M | $33.09M | $29.24M | $25.02M | — | — | — | $6.08M | $2.98M | $827.67K | $2.31M | — | — | — | — | — | — | — | — | — | |
| $19.2M | $16.99M | $11.78M | $10.08M | $1.58M | $161K | $167K | $209K | $235K | $364K | $351K | $355K | $48K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $1.42M | $1.32M | $1.27M | $1.06M | $1.25M | $1.58M | $1.7M | $1.94M | $1.61M | $1.4M | $1.06M | $255K | $37K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $204.71M | $173.85M | $141.55M | $90.12M | $61.29M | $52.65M | $34.02M | $39.21M | $30.07M | $25.43M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $120K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$2.75M | $30.52M | $8.82M | $431K | $1.92M | $1.61M | $385K | -$4.8M | -$5.22M | -$12.16M | -$15.88M | -$14.82M | -$10.15M | -$7.69M | -$4.18M | -$939.23K | -$2.5M | — | — | — | — | — | — | — | — | — | |
| — | 11.21% | 4.42% | 0.33% | 2.17% | 2.23% | 0.79% | -9.37% | -12.61% | -45.43% | -79.64% | -152.55% | -611.27% | -76868.79% | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$1.33M | $31.83M | $10.09M | $1.49M | $3.17M | $3.19M | $2.09M | -$2.86M | -$3.61M | -$10.76M | -$14.83M | -$14.57M | -$10.11M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $22.98M | $24.18M | $22.79M | $21.32M | $7.24M | $5.44M | — | — | — | — | — | — | $3800 | — | $24.66K | $75K | $55.48K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $32.45K | $43.76K | $15.41K | $0 | $512 | — | — | — | — | — | — | — | — | — | |
| — | -$31.88M | -$26.14M | -$24.14M | -$15.93M | -$19.49M | -$3.8M | $4.68M | $19.84M | -$757K | -$3.32M | -$1.08M | $29K | $43.76K | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | -$3.17M | $3.09M | -$2.91M | -$10.13M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$33.43M | -$1.37M | -$17.32M | -$23.71M | -$14.01M | -$17.87M | -$3.42M | -$117K | $14.63M | -$12.92M | -$19.2M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $3.77M | $161K | $701K | $75K | $133K | $4000 | $8000 | — | -$935K | -$111K | $5000 | $3000 | — | $1600 | $0 | — | — | — | — | — | — | — | — | — | — | |
| -$37.23M | -$5.14M | -$17.48M | -$24.41M | -$14.09M | -$18.01M | -$3.36M | $168K | $14.63M | -$11.99M | -$19.09M | -$15.9M | -$10.12M | -$7.64M | -$5.38M | -$953.94K | -$2.53M | -$4.55M | -$3.3M | -$4.28M | -$584.23K | -$539.62K | -$508.23K | -$207.2K | -$228.22K | -$208.42K | |
| — | -1.89% | -8.76% | -18.75% | -15.9% | -24.85% | -6.87% | 0.33% | 35.35% | -44.76% | -95.71% | -163.64% | -609.52% | -76431.24% | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | -$62K | -$293K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$4.99M | — | -$17.48M | -$24.41M | -$14.09M | -$18.48M | -$3.36M | — | — | — | — | — | -$10.12M | -$7.64M | -$5.58M | -$1.05M | -$2.53M | — | — | — | — | — | — | — | — | — | |
| USD/shares | -$0.98 | -$0.14 | -$0.49 | -$0.75 | -$0.51 | -$0.69 | -$0.13 | $0.01 | $0.67 | -$0.60 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$0.97 | -$0.14 | -$0.49 | -$0.75 | -$0.51 | — | -$0.13 | $0.01 | $0.61 | -$0.60 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 36.76M | 35.65M | 32.62M | 27.46M | 26.76M | 25.9M | 25.32M | 21.92M | 20.03M | 12.74M | 9.58M | 9.13M | 8.66M | 4.49M | 397.8K | — | — | — | — | — | — | — | — | — | — |
| shares | — | 36.76M | 35.65M | 32.62M | 27.46M | 26.76M | 25.9M | 26.47M | 23.81M | 20.03M | 12.74M | 9.58M | 9.13M | 8.66M | 4.49M | 397.8K | — | — | — | — | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Showing the latest 26 of 27 periods — chart a line item for full history.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2013–FY2014: $13.19K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
5.77×
Peer median 2.41×
EV/EBIT
—
Peer median 19.69×
P/E (TTM)
—
Peer median 15.79×
Peer medians compare against the 46 similar-size Drug Manufacturers - Specialty & Generic companies (of 95 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Branded | $195,756,000 | $116,115,000 | $50,258,000 | — | — | — |
| Imprimis Rx | $76,547,000 | $83,499,000 | $79,935,000 | — | — | — |
| Pharmaceutical Compounding | — | — | — | $72,476,000 | $48,871,000 | $51,165,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Product Sales Net | $271,909,000 | $198,619,000 | $117,447,000 | $83,524,000 | $69,104,000 | $48,479,000 | $51,137,000 |
| VEVYE | $88,688,000 | $28,061,000 | $1,766,000 | — | — | — | — |
| IHEEZO | $81,348,000 | $49,303,000 | $20,621,000 | — | — | — | — |
| Other Products | $25,326,000 | $37,836,000 | $15,125,000 | — | — | — | — |
| Other Revenue | $394,000 | $915,000 | $12,746,000 | — | — | — | — |
| Other Revenues | $394,000 | $995,000 | $12,746,000 | $5,071,000 | $3,372,000 | $392,000 | $28,000 |
| Commissions | — | — | — | $3,866,000 | $3,253,000 | $356,000 | — |
| Transfer of Acquired Product Sales Profits | — | $995,000 | $12,746,000 | $1,205,000 | — | — | — |
| Transfer of Profit | — | — | — | $1,205,000 | $99,000 | — | — |
| License | — | — | — | — | $20,000 | $36,000 | $28,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Branded | $53,535,000 | $29,257,000 | $18,829,000 |
| Imprimis Rx | $15,124,000 | $31,928,000 | $22,781,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Branded | 27.3% | 25.2% | 37.5% |
| Imprimis Rx | 19.8% | 38.2% | 28.5% |
Key facts
CIK
1360214
CUSIP
415858109
13F (30d)
183 filings
179 filers
Visit website
Investor relations